text
"['\n4. 매출 및 수주상황\n가. 연결기준\xa0\n(단위: 백만원)\n구분\n2024년 3분기\n2023년\n2022년\n사업부문\n품목\n국내\n해외\n합계\n국내\n해외\n합계\n국내\n해외\n합계\n의약품 제조 및 판매\n혈액제제류\n231,148\n135,110\n366,258\n310,639\n180,895\n491,534\n329,493\n136,636\n466,129\nOTC류\n77,614\n355\n77,969\n114,101\n274\n114,375\n141,953\n513\n142,466\n일반제제류\n277,727\n38,901\n316,628\n365,448\n30,274\n395,722\n325,556\n52,190\n377,746\n백신제제\n119,516\n87,785\n207,301\n162,659\n103,218\n265,877\n137,902\n118,518\n256,420\n기타\n192,419\n29,979\n222,398\n224,753\n15,595\n240,348\n259,590\n27,849\n287,439\n검체 등 진단 및 분석\n151,641\n4,751\n156,392\n200,948\n19,342\n220,290\n248,207\n16,167\n264,374\n의료 서비스 및 시스템 개발공급\n165,741\n-\n165,741\n191,663\n-\n191,663\n166,042\n-\n166,042\n임대 및 서비스업\n48,873\n-\n48,873\n59,707\n-\n59,707\n66,770\n-\n66,770\n기타\n205,837\n9,358\n215,195\n215,528\n15,877\n231,405\n191,561\n17,414\n208,975\n보고부문 합계\n1,470,516\n306,239\n1,776,755\n1,845,446\n365,475\n2,210,921\n1,867,074\n369,287\n2,236,361\n연결조정 등\n-\n-\n(136,997)\n\u3000-\n\u3000-\n(152,985)\n(156,801)\n연결재무제표 금액\n\u3000-\n\u3000-\n1,639,758\n-\n-\n2,057,936\n-\n-\n2,079,560\n나. 별도기준\n(단위 : 백만원)\n\xa0 \xa0 \xa0 \xa0 \xa0구 \xa0분\n2024년 3분기\n2023년\n2022년\n영업수익:\n임대료수익\n10,351\n13,474\n14,712\n배당금수익\n20,216\n19,356\n32,779\n기타영업수익\n18,306\n26,877\n26,443\n합계\n48,873\n59,707\n73,934\n다. 수주상황\n(단위 : 백만원 )\n품목\n수주일자\n납기\n수주총액\n기납품액\n수주잔고\n수량\n금액\n수량\n금액\n수량\n금액\n-\n-\n-\n-\n-\n-\n-\n-\n-\n합 계\n-\n-\n-\n-\n-\n-\n']"
